Ronald Richard Biography and Net Worth

Director of Emergent Biosolutions

Mr. Richard has served as a director since January 2005. Mr. Richard has served as the president and chief executive officer of the Cleveland Foundation, the nation’s oldest community foundation, since June 2003. From August 2002 to February 2003, Mr. Richard served as president of Stem Cell Preservation, Inc., a start-up medical research company. After leaving Stem Cell Preservation and prior to joining Emergent BioSolutions, Mr. Richard served as a strategic business advisor for IGEN International, Inc., a biotechnology company. Mr. Richard served as chief operating officer of In-Q-Tel, a venture capital fund that provides technologies to the Central Intelligence Agency, from March 2001 to August 2002. Prior to joining In-Q-Tel, Mr. Richard served in various senior management positions at Matsushita Electric (Panasonic), a consumer electronics company. Mr. Richard is a former U.S. foreign service officer. He served in Osaka/Kobe, Japan and as a desk officer for North Korean, Greek and Turkish affairs at the U.S. Department of State in Washington, D.C. Mr. Richard previously served as chairman of the board of trustees of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. Mr. Richard received an M.A. in international relations from Johns Hopkins University School of Advanced International Studies and a B.A. in history from Washington University. He holds an honorary doctorate in humane letters from Notre Dame College.

What is Ronald Richard's net worth?: The estimated net worth of Ronald Richard is at least $782.42 thousand as of December 5th, 2025. Richard owns 98,417 shares of Emergent Biosolutions stock worth more than $782,415 as of March 27th. This net worth estimate does not reflect any other assets that Richard may own. Learn More about Ronald Richard's net worth.
How do I contact Ronald Richard?: The corporate mailing address for Richard and other Emergent Biosolutions executives is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. Emergent Biosolutions can also be reached via phone at (240) 631-3200 and via email at [email protected]. Learn More on Ronald Richard's contact information.
Has Ronald Richard been buying or selling shares of Emergent Biosolutions?: Ronald Richard has not been actively trading shares of Emergent Biosolutions during the last quarter. Most recently, Ronald Richard sold 21,984 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $11.97, for a transaction totalling $263,148.48. Following the completion of the sale, the director now directly owns 98,417 shares of the company's stock, valued at $1,178,051.49. Learn More on Ronald Richard's trading history.
Who are Emergent Biosolutions' active insiders?: Emergent Biosolutions' insider roster includes Donald Degolyer (Director), Neal Fowler (Director), Coleen Glessner (EVP), Keith Katkin (Director), Richard Lindahl (CFO), Ronald Richard (Director), and Kathryn Zoon (Director). Learn More on Emergent Biosolutions' active insiders.
Are insiders buying or selling shares of Emergent Biosolutions?: During the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 75,366 shares worth more than $749,349.10. The most recent insider tranaction occured on December, 5th when Director Ronald Richard sold 21,984 shares worth more than $263,148.48. Insiders at Emergent Biosolutions own 1.2% of the company. Learn More about insider trades at Emergent Biosolutions.
Information on this page was last updated on 12/5/2025.

Ronald Richard Insider Trading History at Emergent Biosolutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2025	Sell	21,984	$11.97	$263,148.48	98,417
11/25/2022	Sell	1,912	$11.94	$22,829.28	19,837
6/3/2020	Sell	6,572	$87.51	$575,115.72	4,269
5/5/2020	Sell	8,375	$80.19	$671,591.25	8,020
4/27/2020	Sell	7,893	$78.00	$615,654.00	24,288
8/21/2018	Sell	7,893	$60.02	$473,737.86	21,063
8/3/2018	Sell	100	$60.00	$6,000.00	21,063
4/17/2018	Sell	7,893	$55.00	$434,115.00	31,303
12/12/2017	Sell	23,681	$45.02	$1,066,118.62	47,091
9/28/2017	Sell	22,415	$40.00	$896,600.00	24,676
9/27/2017	Sell	1,266	$40.00	$50,640.00	24,676
12/13/2016	Sell	5,900	$34.09	$201,131.00	19,870
12/30/2015	Sell	21,600	$40.00	$864,000.00	13,733
7/13/2015	Sell	4,922	$34.00	$167,348.00
6/29/2015	Sell	4,923	$32.76	$161,277.48
12/26/2014	Sell	5,000	$28.00	$140,000.00
12/17/2014	Sell	5,000	$27.00	$135,000.00

Ronald Richard Buying and Selling Activity at Emergent Biosolutions

Emergent Biosolutions Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $7.95

$7.90

$8.15

50 Day Range

MA: $10.05

$7.99

$12.23

2 Week Range

Now: $7.95

$4.02

$14.06

Volume

638,461 shs

Average Volume

965,982 shs

Market Capitalization

$410.54 million

P/E Ratio

9.46

Dividend Yield

N/A

Beta

2.41